Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced it has entered into an option agreement to purchase up to a 15% equity interest in LyoGenesis Plus for cash ...
Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced that it has entered into a development and manufacturing agreement with MPP Group LLC ("MPP"), a Mequon, ...
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this ...
In the news release, Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group ...
Platform Integrates Three Research Modalities Targeting the Electrical Properties of Tumor Biology in Pancreatic Cancer MEQUON, Wis., May 1, 2026 /PRNewswire/ -- (TSXV: ...
Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or "Company") today announced the appointment of Dr. Alexander Dobranowski and Scott Kelly to its Board of Directors ("Board"), further ...
LODI, Wis., Oct. 2, 2025 /CNW/ -- Vector Science & Therapeutics today announced the appointment of Tabitha Hendren as Director, Engineering and Design. Hendren will report to Chief Technology Officer ...
But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. Given this risk, we thought we'd take a ...
Mequon-based Vector Science & Therapeutics announced that it has entered into an option agreement to purchase up to a 15% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results